TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Blood loss in postoperative drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Treatment-Emergent ≥ Grade 3 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Normal range of motion and proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder aproximation force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Frequency HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High Frequency HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Cold/Flu Symptom Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Adhesion Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: static visual field size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of insulin applications (punctures)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reasons leading to change of the therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient satisfaction with NovoPen® 4 insulin delivery system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delta of the Apnea/Hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: advanced care management
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visual and colorimetric assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Progression free survival at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Global Quality of life of patients with PCPC and PLIC
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Specific Quality of life of patients with PCPC and PLIC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Death Pre vs Post PROGALIAM implantation
Endpoint domain: Mortality/survival
Primary endpoint: MACE Death Pre vs Post PROGALIAM implantation
Endpoint domain: Mortality/survival
Primary endpoint: organ system involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of cognitive disability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: case-fatality
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Experienced Any Thromboembolic (TE) Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in hepatitis C viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Center of Mass Acceleration Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vesical Valsalva leak point pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Fugl-Meyer Test of Arm Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Motor Activity Log
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving removal of invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: urinary sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline in the isotopic ratio of iron in blood at week 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change from baseline in the isotopic ratio of iron in blood at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adoption of Control Tower
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Goal Attainment Scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: prevalence of HEV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: new-infection rate of HEV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Physiologic Biorhythms (heart rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiologic Biorhythms (Skin conductance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of nights with stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Net Ulcer Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor targeting potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Beck Scale for Suicide Ideation (BSS)
Endpoint domain: Adverse events/effects
Primary endpoint: Columbia Suicide Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Beck Hopelessness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in memory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GMT for Anti-JEV Neutralizing Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival without neurological dependency
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of ocular and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve of Alfentanil Concentration vs. Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average heart rate change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average hourly premature ventricular beats change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average hourly repetitive beats change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Compassion Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Secondary Traumatization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Health Risk Behaviors Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severity of substance use problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pet-AV45 cortical binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Log Change of Skin Flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient Global Impression of Change (PGIC) at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: liver biopsy histologic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma AZD9291 concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration time curve from zero to infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of penile corpus cavernosum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival-6
Endpoint domain: Mortality/survival
Primary endpoint: Presence of PAMP in whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: one repetition strength tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: jump tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of esophageal varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in respiratory mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Weight development over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ST-segment elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mortality due to breast and cervical cancer
Endpoint domain: Mortality/survival
Primary endpoint: incidence of breast and cervical cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Impact of COVID-19 on pregnancy outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Measure of Early Graft Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Malformations in Infants
Endpoint domain: Mortality/survival
Primary endpoint: Recovery from Anosmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMR rate
Endpoint domain: Mortality/survival
Primary endpoint: Injection Pain Score (Mean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection Pain Score (Median)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritumoral HFO Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RPTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability Scale for Deployment 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability Scale for Deployment 2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sociability Scale for Deployment 1
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Sociability Scale for Deployment 2
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Acceptability Scale for Deployment 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability Scale for Deployment 2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in MDSC level in patients with localized, muscle-invasive bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in MDSC level in patients with metastatic bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in MDSC level in patients with no history of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in tumor burden evaluated by radiographic imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Live Births Following Uterus Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Number of Surgically Successful Uterus Transplants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Composite measure of safety and toxicity profile
Endpoint domain: Adverse events/effects
Primary endpoint: Target receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defibrillation Threshold (DFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: death/repeated hospitalisation due to heart failure/myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Change of abdominal subcutaneous fat volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Attempts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Needle Tolerance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of invasive ventilator free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severity of Alcohol Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASI Drug Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent Correct on the Knowledge Measure (Objective Knowledge Score)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Decisional Conflict (SURE Measure)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decision Process (Decision Quality Index Subscale)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change From Baseline in Awake Objective Cough Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: LDL Goal Attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in QT duration corrected for heart rate by Fridericia's formula (QTcF) interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in immunologic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Use of NSAIDs or analgesics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety and tolerability of ZACTIMA
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose levels in anal fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage difference in risk levels comparing short term risk and lifetime risk in patients with CKD stage 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with CKD stage 4 in risk categories after assessing short term risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum vitamin D3 half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Point at Which Anti-Xa Activity is Lower Than 0.2 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine oxalate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxygen consumption rate of immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response rates to study invitation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Unplanned Re-hospitalization and Emergency/Urgent Care Visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: HRQOL Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma Cmax of ritonavir-boosted Atazanavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AUC of ritonavir-boosted Atazanavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Clearance of ritonavir-boosted Atazanavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracellular clearance of ritonavir-boosted Atazanavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of pediatric upper gastric intestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Isokinetic trunk muscle flexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isokinetic trunk muscle extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Duration of Use Under Clinical Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall Palatability Visual Analogue Scale (VAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Circulating serum periostin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UPDRS Part 3 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of LAA leak closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Normalization of abnormal test parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of overt encephalopathy
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants undergoing cardiovascular screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Success at Test of Cure (TOC) for the intent-to-treat (ITT) population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Success at Test of Cure (TOC) for the clinically evaluable (CE) population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of non-convulsive seizure and subclinical status epilepticus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Having at Least One Confirmed Herpes Zoster Case
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of pain-free attacks at 120 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum depression diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Glucose Infusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: bioavailability of XL281
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response of bone disease to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cumulative incidence of recurrence of thromboembolic events
Endpoint domain: Mortality/survival
Primary endpoint: Serum cytokine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of lung ultrasound B lines appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Achieving ≥4 Point Reduction in SLEDAI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fecal survival of probiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in serum HIF-1a and VEGF-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Cannabis Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of Cannabis Used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consequences of Cannabis Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Significant Reversal of INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of the Pain Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UKK walk test of 2 km
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HADS (Hospital Anxiety And Depression Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in intraocular pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse Pressure Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Abnormalities in Clinical Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Best Overall Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development of Postoperative Delirium (POD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDASI Score of Chemotherapy-associated Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: mechanical pinprick perceived intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area of increased mechanical pinprick sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resting state EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuron Firing Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Axial Length (Axial Elongation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Duration to run the test battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychiatric well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing